House com­mit­tee ad­vances bills aimed at or­phan ex­clu­siv­i­ty, gener­ic la­bel­ing and con­tin­u­ous man­u­fac­tur­ing

The House En­er­gy and Com­merce Com­mit­tee on Wednes­day ad­vanced 17 health-re­lat­ed bills for con­sid­er­a­tion by the House, sev­er­al of which have im­pli­ca­tions for the FDA’s over­sight of or­phan drugs, im­port­ed med­ical de­vices and la­bel­ing.

Frank Pal­lone

“These bills will ex­pand cov­er­age and ac­cess to care, strength­en men­tal health par­i­ty, pro­vide men­tal health sup­port to first re­spon­ders, en­hance trans­paren­cy and op­er­abil­i­ty of the Strate­gic Na­tion­al Stock­pile and im­prove the safe­ty of Amer­i­ca’s food, drugs and med­ical de­vices,” said Com­mit­tee Chair­man Frank Pal­lone (D-NJ).

One of the bills, H.R. 4712, the Fair­ness in Or­phan Drug Ex­clu­siv­i­ty Act, would re­quire drug­mak­ers seek­ing or­phan ex­clu­siv­i­ty for a prod­uct be­cause it would not be prof­itable to demon­strate that there is no rea­son­able ex­pec­ta­tion that they will re­coup the cost of de­vel­op­ing the drug with­in 12 years of mar­ket­ing in or­der to ob­tain or re­tain or­phan drug ex­clu­siv­i­ty.

An­oth­er bill, H.R. 5663, the Safe­guard­ing Ther­a­peu­tics Act, would give FDA the au­thor­i­ty to de­stroy im­port­ed adul­ter­at­ed, mis­brand­ed or un­ap­proved med­ical de­vices that it deems to be a threat to pub­lic health. The new au­thor­i­ty would build on the agency’s au­thor­i­ty to de­stroy adul­ter­at­ed, mis­brand­ed or coun­ter­feit drugs un­der the Food and Drug Ad­min­is­tra­tion Safe­ty and In­no­va­tion Act.

FDA would gain an­oth­er new au­thor­i­ty un­der H.R. 5668, the Mak­ing Ob­jec­tive Drug Ev­i­dence Re­vi­sions for New La­bel­ing Act of 2020, to re­quire drug­mak­ers to up­date the la­bel­ing of old­er gener­ic drugs when new sci­en­tif­ic ev­i­dence is avail­able re­gard­ing the drugs’ use, to re­flect ac­cept­ed us­es of the drug in clin­i­cal prac­tice that are not cur­rent­ly re­flect­ed in the ap­proved la­bel­ing and when the la­bel­ing does not meet cur­rent le­gal and reg­u­la­to­ry re­quire­ments.

Ad­di­tion­al­ly, H.R. 4866, the Na­tion­al Cen­ters of Ex­cel­lence in Con­tin­u­ous Phar­ma­ceu­ti­cal Man­u­fac­tur­ing Act of 2019, would di­rect FDA to des­ig­nate na­tion­al cen­ters of ex­cel­lence in con­tin­u­ous phar­ma­ceu­ti­cal man­u­fac­tur­ing that would work with the agency and in­dus­try “to craft a na­tion­al frame­work for con­tin­u­ous man­u­fac­tur­ing im­ple­men­ta­tion.” The bill would pro­vide $80 mil­lion in ap­pro­pri­a­tions for des­ig­nat­ed cen­ters of ex­cel­lence each year from FY2021-2025.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Justin Klee (L) and Joshua Cohen, Amylyx co-CEOs (Cody O'Loughlin/The New York Times; courtesy Amylyx)

Ad­vo­cates, ex­perts cry foul over Amy­lyx's new ALS drug, cit­ing is­sues with price, PhI­II com­mit­ment

Not 24 hours after earning the first ALS drug approval in five years, Amylyx Pharmaceuticals’ Relyvrio is already drawing scrutiny. And it’s coming from multiple fronts.

In an investor call Friday morning, Amylyx revealed that it would charge about $158,000 per year, a price point that immediately drew backlash from ALS advocates and some outside observers. The cost reveal had been highly anticipated in the immediate hours after Thursday evening’s approval, though Amylyx only teased Relyvrio would cost less than previously approved drugs.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Land­mark Amy­lyx OK spurs de­bate; Some... pos­i­tive? Alzheimer's da­ta; Can­cer tri­al bot­tle­neck; Sanofi's CRISPR bet; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

After brief stops in Paris and Boston, John Carroll and the Endpoints crew are staying on the road in October with their return for a live/streaming EUBIO22 in London. The hybrid event fireside chats and panels on mRNA, oncology and the crazy public market. We hope you can join him there.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Joshua Cohen (L) and Justin Klee, Amylyx co-CEOs

Up­dat­ed: Af­ter long and wind­ing road, FDA ap­proves Amy­lyx's ALS drug in vic­to­ry for pa­tients and ad­vo­ca­cy groups

For just the third time in its 116-year history, the FDA has approved a new treatment for Lou Gehrig’s disease, or ALS.

US regulators gave the thumbs-up to the drug, known as Relyvrio, in a massive win for patients and their families. The approval, given to Boston-area biotech Amylyx Pharmaceuticals, comes after two years of long and contentious debates over the drug’s effectiveness between advocacy groups and FDA scientists, following the readout of a mid-stage clinical trial in September 2020.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Up­dat­ed: Al­ny­lam re­in­forces APOL­LO-B patisir­an da­ta be­fore head­ing to the FDA

Weeks after uncorking some mostly positive data for patisiran in transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy, Alnylam is bolstering its package with new exploratory and subgroup data before shipping it off to regulators.

The RNAi drug maintained “generally consistent” benefits in efficacy and quality of life across several prespecified subgroups at month 12, Alnylam announced on Friday afternoon, including age, baseline tafamidis use, ATTR amyloidosis type, baseline six-minute walk test score and others.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

#AAO22: J&J’s first look at com­mon eye dis­ease port­fo­lio pads the case for PhII of gene ther­a­py

CHICAGO — While the later-stage drug developers in the geographic atrophy field are near the finish line, Johnson & Johnson’s Janssen is taking a more deliberate route, with a treatment that it hopes to be a one-time fix.

The Big Pharma will take its Hemera Biosciences-acquired gene therapy into a Phase II study later this year in patients with GA, a common form of age-related macular degeneration that impacts about five million people worldwide. To get there, Janssen touted early-stage safety data at the American Academy of Ophthalmology annual conference Saturday morning, half a day after competitors Apellis and Iveric Bio revealed their own more-detailed Phase III analyses.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Jerome Durso, Intercept Pharmaceuticals CEO

In­ter­cep­t's OCA fails a PhI­II NASH tri­al, rais­ing fresh doubts about its years­long quest for an OK

Intercept Pharmaceuticals has run into another big setback in its yearslong quest to win an approval for OCA in NASH. The biotech put out word Friday morning that its Phase III REVERSE study failed the primary endpoint for the liver disease, sending its share price into a tailspin.

There was no significant improvement in fibrosis among the patients suffering from cirrhosis who were treated with obeticholic acid, with investigators hunting for a minimum 1-stage histological improvement in the disease after 18 months of therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.

Bo Cumbo, new Solid Bio CEO

Sol­id Bio gets a new CEO, $75M cash and drops lead drug as big in­vestors ju­ry-rig a merg­er deal

Three months after Endpoints News broke the story that gene therapy outfit AavantiBio had gutted its CMC group in a reorganization, the biotech’s CEO has helped engineer a merger with struggling penny stock player Solid Bio. And he’s going to remain in charge of the combined operation, as Solid founder Ilan Ganot steps aside.

The merger news this morning features some high-profile investors.

Perceptive Advisors, RA Capital Management and Bain Capital Life Sciences are leading a $75 million raise to add to the pool of cash Solid will have after the tie-up. That will leave Solid $215 million in cash as Bain’s Adam Koppel jumps on the board — enough to pay for ops and get through some key data milestones on their way into 2025.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,400+ biopharma pros reading Endpoints daily — and it's free.